Pharminent

Merck’s Keytruda in combination with chemotherapy gets FDA nod to treat NSCLC

Merck’s Keytruda (pembrolizumab) in combination with pemetrexed (Alimta) and carboplatin (pem/carbo) has been approved by the US Food and Drug Administration (FDA) for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. http://www.pharmaceutical-business-review.com/news/mercks-keytruda-regimen-gets-fda-approval-for-metastatic-nsclc-treatment-110517-5811043

Filed under: Cancer, Immunotherapy